Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NewLink-Genentech deal could be worth more than $1bn

This article was originally published in Scrip

Executive Summary

NewLink Genetics has been in the news recently for its experimental ebola vaccine, but the Ames, Iowa-based company's stock jumped 7.1% to $31.44 per share on 20 October based on a cancer immunotherapy deal with Genentech potentially worth more than $1bn.

You may also be interested in...



NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug

Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.

NewLink Absorbs Big Blow As Roche Exits IDO Inhibitor Partnership

Genentech's statements about IDO as an immuno-oncology target raise questions about the future of the drug class, but IDO leader Incyte has emerged unscathed for now.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel